28458-45-9

Usage

Uses

Used in Pharmaceutical Industry:
N-tert-Butyl-2-nitroaniline is used as a reactant for the preparation of benzimidazol-2-ones. These benzimidazol-2-ones are potent, selective, and orally efficacious norepinephrine reuptake inhibitors. They play a crucial role in the development of medications targeting conditions such as attention deficit hyperactivity disorder (ADHD) and depression, where the regulation of norepinephrine levels in the brain is essential for symptom management.

Upstream product

• 88-74-4 2-nitro-aniline 
• 115-11-7 isobutene 
• 75-64-9 tert-butylamine 
• 1493-27-2 ortho-nitrofluorobenzene 
• 88-73-3 2-Chloronitrobenzene 

Downstream Products

• 76060-10-1 2-(2-aminophenyl)-1-(t-butyl)benzimidazole 
• 76060-11-2 2-(2-azidophenyl)-1-(t-butyl)benzimidazole 
• 76060-07-6 2-(2-nitrophenyl)-1-(t-butyl)benzimidazole 
• 76060-04-3 2-(2-nitrophenyl)-1-(t-butyl)-2,3-dihydrobenzimidazole 
• 17582-96-6 1-(tert-butyl)-1H-benzimidazole 
• 129799-89-9 N-tert-butyl-N-ethoxalyl-2-nitroaniline 
• 180207-78-7 (3,5-Dimethyl-piperazin-1-yl)-[3-(4-methoxy-phenyl)-4H-imidazo[1,5-a]quinoxalin-5-yl]-methanone 
• 148891-10-5 (3,5-Dimethyl-piperazin-1-yl)-[3-(4-fluoro-phenyl)-4H-imidazo[1,5-a]quinoxalin-5-yl]-methanone 

Relevant academic research and scientific papers

Molecular Scissors for Tailor-Made Modification of Siloxane Scaffolds

The controlled design of functional oligosiloxanes is an important topic in current research. A consecutive Si?O?Si bond cleavage/formation using siloxanes that are substituted with 1,2-diaminobenzene derivatives acting as molecular scissors is presented.

Biomimetic alloxan-catalyzed intramolecular redox reaction with O2: One-pot atom-economic synthesis of sulfinyl-functionalized benzimidazoles

Given the necessity of sacrificial reductants in various biomimetic aerobic oxygenations, alloxan-catalyzed aerobic redox system for one-pot atom-economic synthesis of sulfinyl-functionalized benzimidazoles was developed by ingeniously binding both the substrate sulfide and sacrificial reductant. This mild and transition-metal-free protocol undergoes two oxidations without additional sacrificial reagents, except for the environmentally benign molecular oxygen.

CRBN LIGANDS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.

Imidoyl dichlorides as new reagents for the rapid formation of 2-aminobenzimidazoles and related azoles

The development of a reagent for the efficient synthesis of five- and six-membered azoles at room temperature is proposed. A variety of substituted 2-aminobenzimidazoles are synthesized in good to excellent yields. The ability to incorporate various protecting groups makes the imidoyl dichloride reagent amenable to a large number of syntheses. The reagent is applied to the total synthesis of the 2-aminobenzimidazole containing carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), from 2-chloro-3-nitropyridine in >60% yield in 6 steps.

GSK-3BETA INHIBITOR

For the purpose of providing a GSK-3β inhibitor containing a 2-aminopyridine compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (IA): wherein each symbol is as defined in the specification. or a salt thereof or a prodrug thereof.

1- Or 3-(3-amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2- ones: Potent, selective, and orally efficacious norepinephrine reuptake inhibitors

Sequential structural modifications of the aryloxypropanamine template (e.g., atomoxetine, 2) led to a novel series of 1-(3-amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors (NRIs). In general, this series of compounds potently blocked the human norepinephrine transporter (hNET) while exhibiting selectivity at hNET against both the human serotonin (hSERT) and dopamine transporters (hDAT). Numerous compounds (e.g., 19-22) had low nonamolar hNET potency with IC 50 values of 7-10 nM and excellent selectivity (>500 fold) at hNET over hSERT and hDAT. Several compounds, such as 20 and 22, were tested in a telemetric rat model of ovariectomized-induced thermoregulatory dysfunction and were efficacious at oral doses of 3 mg/kg in reducing the tail skin temperature. In addition, compound 20 was also studied in the rat hot plate and spinal nerve ligation (SNL) models of acute and neuropathic pain, respectively, and was orally efficacious at doses of 3-10 mg/kg.

Phenylaminopropanol derivatives and methods of their use

The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

4-Hydroxy-5,6-dihydro-2H-pyran-2-ones. 3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1' and S1' of the HIV-1 protease enzyme

56-Dihydro-2H-pyran-2-ones are potent inhibitors of HIV-1 protease which bind to the S1 S2 S1' S2' pockets have a unique binding mode with the catalytic aspartyl groups the flap region of the enzyme. Efforts to explore 3-position heterocyclic scaffolds that bind to the S1' S2' pockets have provided a number of selected analogs that display high HIV-1 protease inhibitory activity.

Design and syntheses of a series of novel serotonin3 antagonists

From a structural comparison study between serotonin and serotonin3 (5- HT3) antagonists using a two-dimensional grid template composed of regular hexagons, we deduced structural modification patterns from agonists to antagonists, an